Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Irene Ghobrial, M.D.

Co-Author

This page shows the publications co-authored by Irene Ghobrial and Lorenzo Trippa.
Connection Strength

1.306
  1. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996.
    View in: PubMed
    Score: 0.226
  2. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389.
    View in: PubMed
    Score: 0.225
  3. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019 11; 94(11):1244-1253.
    View in: PubMed
    Score: 0.215
  4. Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
    View in: PubMed
    Score: 0.209
  5. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018 12 13; 132(24):2608-2612.
    View in: PubMed
    Score: 0.202
  6. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017 04 27; 129(17):2429-2436.
    View in: PubMed
    Score: 0.180
  7. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 07; 182(2):222-230.
    View in: PubMed
    Score: 0.049
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.